Drug reference
Agalsidase alfa, an enzyme produced by recombinant DNA technology are licensed for long-term enzyme replacement therapy in Fabry’s disease (a lysosomal storage disorder caused by deficiency of alpha- galactosidase A).
PDF page 1145
Fabry’s disease (specialist use only) ▶BY INTRAVENOUS INFUSION ▶Adult: 200 micrograms/kg every 2 weeks
PDF page 1145
→Appendix 1: agalsidase alfa
PDF page 1145
▶Common or very common Arrhythmias. asthenia. chest discomfort. chills. cough. diarrhoea. dizziness. dyspnoea . excessive tearing. fever. flushing. gastrointestinal discomfort. headache. hoarseness. hypersomnia. hypertension. increased risk of infection. influenza like illness. joint disorders. malaise. musculoskeletal discomfort. myalgia. nausea. ototoxicity. pain. palpitations. peripheral oedema. peripheral swelling. rhinorrhoea. sensation abnormal. skin reactions. taste altered. temperature sensation altered. throat complaints . tremor. vomiting ▶Uncommon Altered smell sensation. angioedema. hypersensitivity. sensation of pressure ▶Frequency not known Heart failure. hyperhidrosis. hypotension. myocardial ischaemia SIDE-EFFECTS, FURTHER INFORMATION Infusion-related reactions; manage by interrupting the infusion, or minimise by pre-treatment with an antihistamine or corticosteroid — consult product literature.
PDF page 1145
Use with caution.
PDF page 1145
Use with caution—no information available.
PDF page 1145
Administration for intravenous infusion, give intermittently in sodium chloride 0.9%; dilute requisite dose with 100 mL infusion fluid and give over 40 minutes using an in-line filter; use within 3 hours of dilution.
PDF page 1145
There can be variation in the licensing of different medicines containing the same drug. Solution for infusion ▶Replagal (Shire Pharmaceuticals Ltd) Agalsidase alfa 1 mg per 1 ml Replagal 3.5mg/3.5ml solution for infusion vials | 1 vial P £1,049.94
PDF page 1145
200 micrograms/kg every 2 weeks
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1145
